Novo Nordisk Surpasses Q2 Profit Estimates, Lifts Full-Year Guidance
Novo Nordisk reported second-quarter adjusted operating profit that exceeded analyst forecasts and raised its outlook for full-year profit and sales. The Danish drugmaker, led by CEO Mike Doustdar since last year, is pushing a turnaround centered on the recently launched Wegovy pill while pursuing legal action against U.S. rival Eli Lilly over adve…